MAPKAPK2 and atherosclerosis: We have shown that a previously developed non-ATP-competitive allosteric MK2 inhibitor with high specificity, cmpd 28, can improve glucose metabolism in obese mice [9], and now we show that two new inhibitors have benefits for both metabolism and atherosclerosis.